Reversing the poor prognosis of primary amyloid light‑chain amyloidosis with cardiac involvement
Pol Arch Intern Med
.
2022 Apr 28;132(4):16197.
doi: 10.20452/pamw.16197.
Epub 2022 Jan 25.
Authors
Artur Jurczyszyn
1
,
Renata Rajtar-Salwa
2
,
Danuta Sorysz
2
,
Barbara Zawiślak
3
,
Anna Suska
4
,
Marta Szostek
5
Affiliations
1
Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland. mmjurczy@cyf-kr.edu.pl
2
Department of Cardiology and Cardiovascular Interventions, University Hospital, Kraków, Poland
3
Intensive Cardiac Care Unit, University Hospital, Kraków, Poland
4
Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland
5
Department of Hematology, Jagiellonian University Medical College, Kraków, Poland
PMID:
35076194
DOI:
10.20452/pamw.16197
No abstract available
MeSH terms
Amyloidosis* / complications
Amyloidosis* / diagnosis
Humans
Immunoglobulin Light-chain Amyloidosis* / complications
Immunoglobulin Light-chain Amyloidosis* / diagnosis
Prognosis